Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI‐Related Adverse Events During IO–TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study
4 affiliations
- 1Nagoya City University Graduate School of Medical Sciences
- 2Niigata University Graduate School of Medical and Dental Sciences
- 3Wakayama Medical University
- 4Hokkaido University
Abstract
Background Combination therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors (IO–TKI) is a key treatment option for metastatic renal cell carcinoma (mRCC), but distinguishing immune‐related adverse events (irAEs) from TKI‐related adverse events (TKI‐AEs) is challenging because of overlapping clinical features. We aimed to evaluate whether eosinophil counts can help differentiate between them. Methods In this retrospective multicenter study, 123 patients with mRCC treated with IO–TKI therapy were analyzed. Patients were classified into an irAE group (n = 64) and a TKI‐AE group (n = 59). Changes in eosinophil counts from baseline to the start of the second treatment cycle were compared. Receiver operating characteristic (ROC) and logistic regression analyses were performed to assess associations with irAE occurrence. Results Baseline eosinophil counts did not differ between groups. Eosinophil counts at the start of the second treatment cycle were higher in the irAE group than those in the TKI‐AE group (269.6 vs. 189.6 eosinophils/μL; p < 0.05). No significant differences were observed in other blood parameters, including neutrophil, lymphocyte, monocyte, and platelet counts, the neutrophil‐to‐lymphocyte ratio, or the platelet‐to‐lymphocyte ratio. Although the overall discriminatory performance was modest (area under the ROC curve = 0.57, sensitivity = 0.30, specificity = 0.94), eosinophil counts ≥ 380/μL were associated with irAEs in both univariate (odds ratio = 7.21) and multivariable (odds ratio = 8.39; p < 0.05) analyses. Conclusions Early increases in eosinophil counts were associated with irAEs and may help distinguish irAEs from TKI‐AEs during IO–TKI therapy. Given their high specificity but limited sensitivity, eosinophil counts may have utility as an adjunctive rather than stand‐alone marker, and prospective validation is warranted.
Related
- Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis.
- Changes in Treatment Patterns and Survival Outcomes Across Therapeutic Eras in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study.
- Bedside Bioimpedance and Simple Functional Tests Identify Muscle Function Impairment Predicting Overall Survival in Chemotherapy-treated Metastatic Urothelial Carcinoma: A Retrospective Pilot Study
- Real-world treatments and outcomes in metastatic and recurrent esophageal squamous cell carcinoma in Japan: a retrospective analysis using the Millennial Medical Record database
- Lymph Node Regression Improves Prognostic Stratification in Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Cohort Study.
BibTeX
@article{tomita2026eosinophil,
title = {{Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI‐Related Adverse Events During IO–TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study}},
author = {Misato Tomita and Yoshihiko Tasaki and Shuzo Hamamoto and Takahiro Osawa and Shimpei Yamashita and Ryuji Matsumoto and Hiroaki Ikoma and Kengo Kawase and Yoshihisa Mimura and Yosuke Sugiyama and Takahiro Yasui and Yoko Furukawa‐Hibi},
journal = {Cancer medicine},
year = {2026},
month = oct,
doi = {10.1002/cam4.72422},
url = {https://europepmc.org/article/PMC/PMC13691297},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI‐Related Adverse Events During IO–TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study
AU - Misato Tomita
AU - Yoshihiko Tasaki
AU - Shuzo Hamamoto
AU - Takahiro Osawa
AU - Shimpei Yamashita
AU - Ryuji Matsumoto
AU - Hiroaki Ikoma
AU - Kengo Kawase
AU - Yoshihisa Mimura
AU - Yosuke Sugiyama
AU - Takahiro Yasui
AU - Yoko Furukawa‐Hibi
PY - 2026
DA - 2026/10/01
JO - Cancer medicine
DO - 10.1002/cam4.72422
UR - https://europepmc.org/article/PMC/PMC13691297
AB - Background Combination therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors (IO–TKI) is a key treatment option for metastatic renal cell carcinoma (mRCC), but distinguishing immune‐related adverse events (irAEs) from TKI‐related adverse events (TKI‐AEs) is challenging because of overlapping clinical features. We aimed to evaluate whether eosinophil counts can help differentiate between them. Methods In this retrospective multicenter study, 123 patients with mRCC treated with IO–TKI therapy were analyzed. Patients were classified into an irAE group (n = 64) and a TKI‐AE group (n = 59). Changes in eosinophil counts from baseline to the start of the second treatment cycle were compared. Receiver operating characteristic (ROC) and logistic regression analyses were performed to assess associations with irAE occurrence. Results Baseline eosinophil counts did not differ between groups. Eosinophil counts at the start of the second treatment cycle were higher in the irAE group than those in the TKI‐AE group (269.6 vs. 189.6 eosinophils/μL; p < 0.05). No significant differences were observed in other blood parameters, including neutrophil, lymphocyte, monocyte, and platelet counts, the neutrophil‐to‐lymphocyte ratio, or the platelet‐to‐lymphocyte ratio. Although the overall discriminatory performance was modest (area under the ROC curve = 0.57, sensitivity = 0.30, specificity = 0.94), eosinophil counts ≥ 380/μL were associated with irAEs in both univariate (odds ratio = 7.21) and multivariable (odds ratio = 8.39; p < 0.05) analyses. Conclusions Early increases in eosinophil counts were associated with irAEs and may help distinguish irAEs from TKI‐AEs during IO–TKI therapy. Given their high specificity but limited sensitivity, eosinophil counts may have utility as an adjunctive rather than stand‐alone marker, and prospective validation is warranted.
SN - 2045-7634
ER -